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Abstract (200 words max.): 
 
Purpose of review: 
Anaemia affects up to 50% of pregnancies worldwide and is associated with maternal and 
neonatal morbidity and mortality. Prevention and management of anaemia remains a priority. 
Despite this, there is ongoing debate on the optimal approach to identifying anaemia in 
pregnant women and the best strategies for prevention and management. The objective of this 
review is to describe the current landscape of haemoglobin testing in pregnancy in low and 
high income countries.  
 
Recent findings: 
Current definitions of anaemia in pregnancy comprise a laboratory threshold of haemoglobin 
below which treatment is offered. Haemoglobin measurement is not sensitive in detecting 
iron deficiency, the most common cause of maternal anaemia. Furthermore, these historical 
thresholds were derived from heterogeneous populations comprising men and women. 
Women with anaemia in pregnancy are offered iron therapy, without testing for the 
underlying cause. This may be appropriate in high income settings, where iron deficiency is 




Current thresholds of haemoglobin defining anaemia in pregnancy are under review. Further 
research and policy should focus on optimal strategies to identify women at risk of anaemia 












LMIC: low and middle-income country  
LLINs: long-lasting insecticidal nets LLINs 
IPTP: intermittent preventive treatment in pregnancy  





Testing for anaemia in pregnancy is ubiquitous across low and high income countries and 
usually begins at the booking (first antenatal) appointment. Screening may range from 
looking for risk factors and clinical features of anaemia in the history, to point of care testing 
or laboratory assessment of the full blood count with or without assessment of iron 
parameters from a venous sample. (1) Which of these provides the most reliable and cost 
effective assessment remains unanswered. In this review, we will provide an overview of the 
landscape of the literature surrounding the use of haemoglobin as a screening tool for 
anaemia in pregnancy, the implications this has on clinical care, resource allocation and 
national and international policy.  
 
Why is anaemia screening important?  
It is widely acknowledged that anaemia in pregnancy is associated with significant morbidity 
and mortality (if severe) for the mother, independently of other factors. (2) Anaemia, if 
combined with other risks (such as emergency delivery) increases adverse outcomes multi-
fold. (3) 
Anaemia has also been associated with adverse outcomes for the developing baby, including 
low birth weight and preterm delivery. (4)  This relationship has been demonstrated to be 
non-linear (5) meaning low and high values of haemoglobin are both detrimental to fetal 
growth and health. This calls into question the safety of unselected routine iron 
supplementation without testing for anaemia or iron deficiency. 
 
High-income countries  
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The British Society for Haematology (BSH), RCOG and NICE guidelines recommend 
routine testing for anaemia at 12 and 28 weeks of pregnancy. (6) UK guidelines stress the 
importance of early identification and management of iron deficiency.  As iron deficiency is 
the most common cause of maternal anaemia in high income settings, the UK guidelines 
recommend initiating oral iron supplements empirically to anaemic women, and using 
haemoglobin response as a diagnostic aid. This reduces the need for additional screening tests 
and avoids delays in management.   
These strategies may miss non-anaemic iron depleted women if attention is not paid to those 
who may be at risk. (7)  One study showed 42% of non-anaemic women in the first trimester 
had a marker of iron deficiency. (8) This may make a case for routine iron supplementation. 
However, in 2015, a review by the U.S. Preventive Services Task Force concluded that, while 
routine supplementation improved haematological parameters, there was insufficient 
evidence of improved maternal and infant outcomes. This is an area of ongoing debate, with 
recent rebuttals suggesting that routine iron supplementation does indeed improve clinical 
outcomes, (8) however, trial level data are lacking. Currently, routine administration of iron 
interventions to all pregnant women in high income settings is not recommended. (7) 
The ongoing high prevalence of anaemia globally and the lack of evidence demonstrating 
safety and efficacy of routine iron supplementation in pregnancy highlights unmet clinical 
and research needs.  
 
Low and middle income countries  
 
More than 1.6 billion people are anaemic, with 42% of all pregnant women worldwide 
affected. (9) The prevalence and severity of anaemia is highest in low and middle-income 
countries and is a public health concern, with the highest rates and mortality associated with 
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the condition being found in South and South East Asia, and Sub-Saharan Africa. (10) In 
these settings the causes of anaemia are often complex, however the global focus currently 
remains on iron deficiency anaemia.  (11) Although iron deficiency is thought to be the major 
cause of anaemia, thought to account for around 50% of anaemia, there is little evidence to 
support such estimates,(12) with a fall in haemoglobin attributed to iron deficiency, without 
objective testing. (13) The limitations of existing indicators to measure iron status at a 
population level and scarcity of data prevent clear understanding of the relative contribution 
of iron deficiency to anaemia prevalence estimates in different geographical settings.  
Although some anaemia prevention strategies have proven successful, (14) anaemia 
continues to pose a considerable public health burden, particularly in pregnancy. (15) Better 
understanding of the causes of anaemia, testing methods and treatment of the underlying 
cause may go a long way to reducing the associated burden.  A more comprehensive and 
holistic approach then just iron supplementation is needed.   
 
The World Health Organization also recommends that all pregnant women are routinely 
screened for anaemia. (1) Those found to be anaemic should be offered daily iron 
supplementation and those not yet anaemic offered iron and folic acid weekly. (1) The 
effectiveness of this strategy in reducing rates of anaemia worldwide is unclear. Particularly 
within LMICs, where anaemia has many potential causes and contributors besides iron 
deficiency, including genetic causes, inflammation, infections both viral and parasitic; such 
as helminth, malaria and HIV and malnutrition and micronutrient deficiencies. Below we 
discuss a few key issues briefly.  
 
Nutritional deficiencies  
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Poor diet and food scarcity in vulnerable groups, including pregnant women worsen 
nutritional anemias including those such as iron, B12 and folate, all of which cause a fall in 
haemoglobin.  (16) While each micronutrients have specific roles, multiple deficiencies tend 
to cluster within individuals, acting synergistically increasing the burden of disease. In these 
individuals, iron supplementation alone is unlikely to lead to anaemia resolution.  
 
Soil-transmitted helminths 
Infectious diseases such as hookworm reduce absorption and metabolism of key 
micronutrients (notably iron) in addition to increasing gastrointestinal tract losses. 
Hookworm infections contribute greatly to the high prevalence of anaemia in sub-Saharan 
Africa and Southeast Asia, with an estimated 576–740 million infections. (17)  There are 
clear benefits from pooled estimates of randomized controlled trials of deworming and 
concomitant iron supplementation strategies showing improvements in mean haemoglobin 
concentration across sub-Saharan Africa. (18) As a result, the current WHO recommendation 
for preventive chemotherapy (deworming) include using single-dose albendazole (400 mg) or 
mebendazole (500 mg), as a public health intervention for pregnant women, after the first 
trimester, living in areas where both anaemia and soil transmitted helminth infections are 
considered endemic. (19) 
 
Malaria 
Malarial infection, particularly plasmodium falciparum can lead to and worsen preexisting 
anaemia.(20) The balance of iron supplementation in the context of malarial infection 
(suspected or confirmed) requires careful consideration; it has been an area of considerable 
debate. (20, 21) In areas such as Africa, WHO recommends prevention and treatment of 
malaria during pregnancy using of long-lasting insecticidal nets (LLINs); in all areas with 
moderate to high malaria transmission in Africa, intermittent preventive treatment in 
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pregnancy (IPTP) with sulfadoxine-pyrimethamine (SP), as part of antenatal care services 
and prompt diagnosis and effective treatment of malaria infections.(1) 
 
HIV related causes 
HIV infection and anaemia are closely related, with anaemia being both a common 
complication in addition to being a marker of disease progression.(22, 23) HIV/AIDS-related 
anaemia is more common in sub-Saharan Africa. The mechanism of HIV/AIDS-related 
anaemia is complex, and beyond the scope of this review. Anaemia is known directly result 
from HIV infection and anaemia of chronic disease, and indirectly affected by antiretroviral 
therapy and AIDS-related illnesses. (23) 
 
Genetic causes 
Haemoglobin disorders affect populations in LMICs disproportionately more than other areas 
of the world, particularly Africa and South East Asian regions where 18.2% and 6.6% of the 
population, respectively, carry a significant haemoglobin variant, as a result affecting more 
than 7% of pregnant women worldwide. (24) Although a known cause of anaemia, their 
contribution to the global anaemia burden is unclear.  The safety of iron supplementation in 
pregnant women with haemoglobinopathies, particularly at high doses is unclear, (25) 
although some limited data suggest iron overload is unlikely to occur. (26) 
 
Distinguishing the underlying causes of anaemia requires clinical observation and expensive 
laboratory investigation, beyond the scope of many regions in LMIC settings.  
 




Haemoglobin, as a test is reported along a continuous scale. The current definitions of 
anaemia are based on laboratory values taken from a healthy population where two standard 
deviations below the lower limit of normal distribution are considered abnormal (classically 
105 g/L in pregnancy, to account for plasma volume dilution). Values of haemoglobin below 
this disease defining threshold necessitate treatment, but cannot suggest what treatment 
should be offered, as a fall in haemoglobin is multifactorial. Consequently, the disease-
defining threshold for anaemia, particularly in pregnancy, needs to be considered with 
caution. There is increasing awareness that the evidence base behind widely used thresholds 
for anaemia and iron biomarkers in pregnancy is poor. (27, 28) Moreover, the reference 
ranges of haemoglobin determining anaemia in pregnancy were developed using data from 
unselected cohorts of individuals including men and non-pregnant women. (29, 30)  
Many argue the widely used thresholds for anaemia in pregnancy are not accurate, (31) 
particularly as these historical reference ranges did not account for geographical or ethnic 
variation, in addition to the burden of infectious disease which undoubtedly will influence the 
distribution of laboratory blood values in any population and especially pregnant women. (32, 
33) 
This leads to the question: are the strategies we are using for identifying anaemic women fit 
for purpose?  Perhaps not. Currently there is ongoing work by WHO to look at the evidence 
behind anaemia defining haemoglobin levels used in clinical practice and research, which 
may change the tide in this area. (31, 34) 
 
What does this mean for clinicians?  
 
A threshold based approach to make treatment decision is longstanding in numerous areas of 
medicine. (35) However, changing disease defining thresholds (for example if anaemia was 
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defined as a haemoglobin level <120 g/L rather than 110), will have profound consequences 
on numerous aspects of care.  For example, having anaemia precludes blood donation, a vital 
resource with limited availability worldwide. (36) New definitions of anaemia (especially if 
the thresholds are increased) will have a profound effect on the number of eligible donors and 
consequently blood stores available, particularly in emergency settings such as obstetric 
haemorrhage.  
 
If a consensus on the definition of anaemia is currently in a state of flux, what does this mean 
for determining the effectiveness of treatment?  Most randomised controlled trials of iron 
treatments in pregnancy have a change in haemoglobin, or prevention of anaemia and 
avoidance of blood transfusion as primary outcomes. (37) The findings of these studies in 
turn drive policy and clinical guidelines. As a consequence, guidelines and policy may be 
frustratingly vague.  Until these issues are resolved, it is important for clinicians to consider 
that individual pregnant women will experience anaemia related symptoms, even if their 
blood parameters do not suggest overt anaemia.  Treatment decisions for these women must 
be made on more than blood values alone. It is also important to recognise that causes of 
anaemia beyond iron deficiency should be considered and providing iron interventions is not 




What next?  
There are emerging Australian data suggesting testing and treatment of non-anaemic iron 
deficiency would be beneficial in reducing transfusion post-delivery, however this has not 




There are limited data on the use of other laboratory tests as screening tools. In routine 
clinical practice a low haemoglobin, mean cell volume (MCV) and mean cell haemoglobin 
(MCH), and mean cell haemoglobin concentration (MCHC) are suggestive of iron deficiency, 
but need cautious interpretation. A recently published study in Sri Lanka found MCHC to be 
sensitive marker for iron deficiency, performing well compared to haemoglobin and MCV. 
However, further testing and cost effectiveness analyses would be required before this could 
be implemented outside of research. (39)  
Testing for specific causes of anaemia, for example markers of iron status such as, but not 
limited to serum ferritin and transferrin levels are fraught with complexity in pregnancy, due 
to the physiological changes.(40)  Normal ranges for these markers in pregnancy have not 
been validated and the currently used thresholds of serum ferritin to diagnosed iron 
deficiency are based on less than ideal data. (28) 
Other markers such as serum hepcidin (a key homeostatic regulator of iron metabolism) are 




Haemoglobin is still widely used as a screening tool for anaemia in pregnancy. In the UK, a 
fall in haemoglobin is most commonly as a result of iron deficiency and so current guidelines 
recommend oral iron therapy as first line management. In LMIC settings, iron 
supplementation alone is unlikely to improve anaemia prevalence.  
 




Key points  
 A haemoglobin level below a particular threshold defines anaemia. Currently used 
thresholds are based on poor evidence and are currently under review 
 Anaemia is caused by a variety of factors, the most common of which is a deficiency 
of iron. Treatment for anaemia with iron interventions without testing for the 
underlying cause is widespread 
 The application of other laboratory tests in pregnancy is currently limited.  
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